(2023) designed a multi-epitope peptide vaccine targeting MAGE-A3, MAGE-A4, and NY-ESO-1 for mucosal melanoma patients, demonstrating significant CTL activation (38). This evidence concerns the gene MAGEA3 and melanoma.